Baird analyst David Rescott lowered the firm’s price target on Medtronic (MDT) to $93 from $96 and keeps a Neutral rating on the shares. The firm said while FY25’s HSD EPS growth exit rate remains a positive out-year indicator, into FY26 the company will contend with ongoing FX pressures, dilutive new product/capital rollouts and a slight tax headwind which Baird thinks will limit a sustainable return to HSD EPS growth.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target lowered to $98 from $106 at Wells Fargo
- Medtronic Reports Strong Q2 2025 Results, Raises Guidance
- Trump Trade: President-elect seeks to kill Biden fuel-efficiency rules
- Morning Movers: Walmart jumps following quarterly results
- MDT Earnings: Medtronic Beats Q2 Expectations, Boosts FY25 Guidance